摘要
目的探讨戈舍瑞林联合芳香化酶抑制剂对绝经前转移性乳腺癌患者骨密度的影响。方法选取120例绝经前转移性乳腺癌患者为研究对象,随机分为两组,对照组使用他莫昔芬治疗,实验组使用戈舍瑞林联合芳香化酶抑制剂治疗,观察两组患者在治疗不同时段骨密度、血清雌二醇及促卵泡激素的变化。结果实验组在治疗后各个时段骨密度均显著低于对照组(P<0.05或P<0.01);实验组在治疗后各个时段雌二醇及促卵泡激素水平均较治疗前下降,与对照组比较差异有统计学意义(P<0.01),对照组治疗前后雌二醇及促卵泡激素水平无明显变化(P>0.05)。结论内分泌治疗可导致绝经前转移性乳腺癌患者骨量丢失,戈舍瑞林联合芳香化酶抑制剂对骨密度的影响更明显。
Objective To evaluate the effect of goserelin combined with aromatase inhibitor on bone mineral density in the premenopausal patients with metastatic breast cancer. Methods A total of 120 premenopausal patients with metastatic breast cancer were enrolled in this study. All the cases were randomly assigned into two groups, each group has 60 cases. The experimental group received goserelin for ovarian castration combined with aromatase inhibitor （anastrozole, letrozole ） and the control group received routine tamoxifen monotherapy. The bone mineral density, serum levels of estradiol and follicle stimulating hormone in two groups were compared at different time points. Results The decline of bone mineral density in experimental group was more remarkable at different time points after treatment than in control group （ P 〈 0.05 or P 〈 0.01 ）. Serum levels of estradiol and follicle stimulating hormone in experimental group were decreased significantly after treatment than before, and furthermore the decline was more obvious than in control group （ P 〈 0.01 ）. Serum hormone levels before and after treatment in control group had no dramatic change （P 〉 0.05 ）. Conclusion A bone mineral loss will occur when premenopausal patients with metastatic breast cancer are treated with endocrine treatment, and its effect is more obvious if patients are treated with goserelin combined with aromatase inhibitor.
出处
《实用临床医药杂志》
CAS
2016年第13期56-58,共3页
Journal of Clinical Medicine in Practice
基金
河北省卫生厅科研项目(13010520152128)
中国高校医学期刊临床专项资金(11529048)
关键词
转移性乳腺癌
绝经前
戈舍瑞林
芳香化酶抑制剂
骨密度
metastatic breast cancer
premenopausal
goserelin
aromatase inhibitor
bone mineral density
